Search

Your search keyword '"Brouwers, Frank P."' showing total 4 results
Start Over Author "Brouwers, Frank P." Topic cardiovascular disease
4 results on '"Brouwers, Frank P."'

1. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

Author

Willeit, Peter, Tschiderer, Lena, Allara, Elias, Reuber, Kathrin, Seekircher, Lisa, Gao, Lu, Liao, Ximing, Lonn, Eva, Gerstein, Hertzel C, Yusuf, Salim, Brouwers, Frank P, Asselbergs, Folkert W, Van Gilst, Wiek, Anderssen, Sigmund A, Grobbee, Diederick E, Kastelein, John JP, Visseren, Frank LJ, Ntaios, George, Hatzitolios, Apostolos I, Savopoulos, Christos, Nieuwkerk, Pythia T, Stroes, Erik, Walters, Matthew, Higgins, Peter, Dawson, Jesse, Gresele, Paolo, Guglielmini, Giuseppe, Migliacci, Rino, Ezhov, Marat, Safarova, Maya, Balakhonova, Tatyana, Sato, Eiichi, Amaha, Mayuko, Nakamura, Tsukasa, Kapellas, Kostas, Jamieson, Lisa M, Skilton, Michael, Blumenthal, James A, Hinderliter, Alan, Sherwood, Andrew, Smith, Patrick J, Van Agtmael, Michiel A, Reiss, Peter, Van Vonderen, Marit GA, Kiechl, Stefan, Klingenschmid, Gerhard, Sitzer, Matthias, Stehouwer, Coen DA, Uthoff, Heiko, Zou, Zhi-Yong, Cunha, Ana R, Neves, Mario F, Witham, Miles D, Park, Hyun-Woong, Lee, Moo-Sik, Bae, Jang-Ho, Bernal, Enrique, Wachtell, Kristian, Kjeldsen, Sverre E, Olsen, Michael H, Preiss, David, Sattar, Naveed, Beishuizen, Edith, Huisman, Menno V, Espeland, Mark A, Schmidt, Caroline, Agewall, Stefan, Ok, Ercan, Aşçi, Gülay, De Groot, Eric, Grooteman, Muriel PC, Blankestijn, Peter J, Bots, Michiel L, Sweeting, Michael J, Thompson, Simon G, Lorenz, Matthias W, PROG-IMT And The Proof-ATHERO Study Groups, Group, PROG-IMT Study, Group, Proof-ATHERO Study, Vascular Medicine, Medical Psychology, APH - Mental Health, APH - Personalized Medicine, Experimental Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Global Health, APH - Aging & Later Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Pulmonary hypertension & thrombosis, Ege Üniversitesi, MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: HVC Pieken Maastricht Studie (9), Interne Geneeskunde, MUMC+: MA Interne Geneeskunde (3), Allara, Elias [0000-0002-1634-8330], Apollo - University of Cambridge Repository, Cardiovascular Centre (CVC), Internal medicine, Nephrology, and ACS - Diabetes & metabolism

Subjects
Male, medicine.medical_specialty, Carotid Artery, Common, carotid intima-media thickness, LDL TREATMENT STRATEGIES, Myocardial Infarction, surrogate marker, TYPE-2 DIABETES-MELLITUS, HIV-INFECTED PATIENTS, 030204 cardiovascular system & hematology, Impaired glucose tolerance, EXTENDED-RELEASE NIACIN, 03 medical and health sciences, 0302 clinical medicine, IMPAIRED GLUCOSE-TOLERANCE, ESTROGEN PLUS PROGESTIN, cardiovascular disease, Physiology (medical), Internal medicine, BASE-LINE CHARACTERISTICS, medicine, Humans, CORONARY-HEART-DISEASE, 030212 general & internal medicine, Myocardial infarction, cardiovascular diseases, Stroke, Randomized Controlled Trials as Topic, clinical trials as topic, business.industry, Surrogate endpoint, Middle Aged, medicine.disease, Common, Clinical trial, meta-analysis, ARTERIAL-WALL THICKNESS, Intima-media thickness, JAPAN STATIN TREATMENT, Heart Disease Risk Factors, Relative risk, Meta-analysis, Cardiology, cardiovascular system, Female, Carotid Artery, Cardiology and Cardiovascular Medicine, business
Abstract

Background: To quantify the association between effects of interventions on carotid intima-media thickness (cIMT) progression and their effects on cardiovascular disease (CVD) risk. Methods: We systematically collated data from randomized, controlled trials. cIMT was assessed as the mean value at the common-carotid-artery; if unavailable, the maximum value at the common-carotid-artery or other cIMT measures were used. the primary outcome was a combined CVD end point defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. We estimated intervention effects on cIMT progression and incident CVD for each trial, before relating the 2 using a Bayesian meta-regression approach. Results: We analyzed data of 119 randomized, controlled trials involving 100 667 patients (mean age 62 years, 42% female). Over an average follow-up of 3.7 years, 12 038 patients developed the combined CVD end point. Across all interventions, each 10 mu m/y reduction of cIMT progression resulted in a relative risk for CVD of 0.91 (95% Credible Interval, 0.87-0.94), with an additional relative risk for CVD of 0.92 (0.87-0.97) being achieved independent of cIMT progression. Taken together, we estimated that interventions reducing cIMT progression by 10, 20, 30, or 40 mu m/y would yield relative risks of 0.84 (0.75-0.93), 0.76 (0.67-0.85), 0.69 (0.59-0.79), or 0.63 (0.52-0.74), respectively. Results were similar when grouping trials by type of intervention, time of conduct, time to ultrasound follow-up, availability of individual-participant data, primary versus secondary prevention trials, type of cIMT measurement, and proportion of female patients. Conclusions: the extent of intervention effects on cIMT progression predicted the degree of CVD risk reduction. This provides a missing link supporting the usefulness of cIMT progression as a surrogate marker for CVD risk in clinical trials., Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P 32488]; Dr-Johannes-and-Hertha-Tuba Foundation; German Research FoundationGerman Research Foundation (DFG) [DFG Lo 1569/2-1, DFG Lo 1569/2-3]; excellence initiative "Competence Centers for Excellent Technologies" (COMET) of the Austrian Research Promotion Agency (FFG) "Research Center of Excellence in Vascular Ageing: Tyrol, VAS-Cage" - Bundesministerium fur Verkehr, Innovation und Technologie (B [843536]; Bundesministerium fur Bildung, Wissenschaft und Forschung (BMWFW); Wirtschaftsagentur Wien; Standortagentur Tirol, This work was supported by the Austrian Science Fund (FWF; P 32488); the Dr-Johannes-and-Hertha-Tuba Foundation; the German Research Foundation (DFG Lo 1569/2-1 and DFG Lo 1569/2-3); and the excellence initiative "Competence Centers for Excellent Technologies" (COMET) of the Austrian Research Promotion Agency (FFG) "Research Center of Excellence in Vascular Ageing: Tyrol, VAS-Cage" (K-Project No. 843536), funded by Bundesministerium fur Verkehr, Innovation und Technologie (BMVIT), Bundesministerium fur Bildung, Wissenschaft und Forschung (BMWFW), Wirtschaftsagentur Wien, and Standortagentur Tirol.

Published
2020

2. The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale.

Author

Tschiderer, Lena, Seekircher, Lisa, Klingenschmid, Gerhard, Izzo, Raffaele, Baldassarre, Damiano, Iglseder, Bernhard, Calabresi, Laura, Liu, Jing, Price, Jackie F., Bae, Jang-Ho, Brouwers, Frank P., de Groot, Eric, Schmidt, Caroline, Bergström, Göran, Aşçi, Gülay, Gresele, Paolo, Okazaki, Shuhei, Kapellas, Kostas, Landecho, Manuel F., and Sattar, Naveed

Subjects
CAROTID intima-media thickness, ATHEROSCLEROTIC plaque, CORONARY disease, LONGITUDINAL method, ATHEROSCLEROSIS, TOOTHBRUSHES, META-analysis
Abstract

Atherosclerosis - the pathophysiological mechanism shared by most cardiovascular diseases - can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid plaque, -ankle-brachial index, pulse wave velocity, and coronary -artery calcium. The Prospective Studies of Atherosclerosis -(Proof-ATHERO) consortium (https://clinicalepi.i-med.ac.at/research/proof-athero/) collates de-identified individual-participant data of studies with information on atherosclerosis measures, risk factors for cardiovascular disease, and incidence of cardiovascular diseases. It currently comprises 74 studies that involve 106,846 participants from 25 countries and over 40 cities. In summary, 21 studies recruited participants from the general population (n = 67,784), 16 from high-risk populations (n = 22,677), and 37 as part of clinical trials (n = 16,385). Baseline years of contributing studies range from April 1980 to July 2014; the latest follow-up was until June 2019. Mean age at baseline was 59 years (standard deviation: 10) and 50% were female. Over a total of 830,619 person-years of follow-up, 17,270 incident cardiovascular events (including coronary heart disease and stroke) and 13,270 deaths were recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum, respectively. The consortium is coordinated by the Clinical Epidemiology Team at the Medical University of Innsbruck, Austria. Contributing studies undergo a detailed data cleaning and harmonisation procedure before being incorporated in the Proof-ATHERO central database. Statistical analyses are being conducted according to pre-defined analysis plans and use established methods for individual-participant data meta-analysis. Capitalising on its large sample size, the multi-institutional collaborative Proof-ATHERO consortium aims to better characterise, understand, and predict the development of atherosclerosis and its clinical consequences. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

3. Urinary potassium excretion and risk of cardiovascular events.

Author

Kieneker, Lyanne M., Gansevoort, Ron T., de Boer, Rudolf A., Brouwers, Frank P., Feskens, Edith J. M., Geleijnse, Johanna M., Navis, Gerjan, Bakker, Stephan J. L., and Joosten, Michel M.

Subjects
CARDIOVASCULAR disease diagnosis, CARDIOVASCULAR diseases, PATIENTS, CARDIOVASCULAR disease treatment, ALCOHOL drinking & health, HEALTH, SMOKING, ALBUMINURIA, EDUCATIONAL attainment, ANTHROPOMETRY, BLOOD pressure, CONFIDENCE intervals, CORONARY disease, STATISTICAL correlation, ALCOHOL drinking, HEART failure, LONGITUDINAL method, MAGNESIUM, SCIENTIFIC observation, POTASSIUM, PROBABILITY theory, RESEARCH funding, SODIUM, STATISTICAL hypothesis testing, STROKE, BODY mass index, PROPORTIONAL hazards models, DATA analysis software, DESCRIPTIVE statistics, ODDS ratio, DIAGNOSIS
Abstract

Background: Observational studies on dietary potassium and risk of cardiovascular disease (CVD) have reported weak-to-modest inverse associations. Long-term prospective studies with multiple 24-h urinary samples for accurate estimation of habitual potassium intake, however, are scarce. Objective: We examined the association between urinary potassium excretion and risk of blood pressure–related cardiovascular outcomes. Design: We studied 7795 subjects free of cardiovascular events at baseline in the Prevention of Renal and Vascular End-stage Disease study, a prospective, observational cohort with oversampling of subjects with albuminuria at baseline. Main cardiovascular outcomes were CVD [including ischemic heart disease (IHD), stroke, and vascular interventions], IHD, stroke, and new-onset heart failure (HF). Potassium excretion was measured in two 24-h urine specimens at the start of the study (1997–1998) and midway through follow-up (2001–2003). Results: Baseline median urinary potassium excretion was 70 mmol/24 h (IQR: 56–84 mmol/24 h). During a median follow-up of 10.5 y (IQR: 9.9–10.8 y), a total of 641 CVD, 465 IHD, 172 stroke, and 265 HF events occurred. After adjustment for age and sex, inverse associations were observed between potassium excretion and risk [HR per each 26- mmol/24-h (1-g/d) increase; 95% CI] of CVD (0.87; 0.78, 0.97) and IHD (0.86; 0.75, 0.97), as well as nonsignificant inverse associations for risk of stroke (0.85; 0.68, 1.06) and HF (0.94; 0.80, 1.10). After further adjustment for body mass index, smoking, alcohol consumption, education, and urinary sodium and magnesium excretion, urinary potassium excretion was not statistically significantly associated with risk (multivariable- adjusted HR per 1-g/d increment; 95% CI) of CVD (0.96; 0.85, 1.09), IHD (0.90; 0.81, 1.04), stroke (1.09; 0.86, 1.39), or HF (0.99; 0.83, 1.18). No associations were observed between the sodium-to-potassium excretion ratio and risk of CVD, IHD, stroke, or HF. Conclusion: In this cohort with oversampling of subjects with albuminuria at baseline, urinary potassium excretion was not independently associated with a lower risk of cardiovascular events. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

4. The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale

Author

Zhiyong Zou, Dorota A. Zozulińska-Ziółkiewicz, Raffaele Izzo, Lena Tschiderer, Manuel F. Landecho, Kuo Liong Chien, Stefan Kiechl, Damiano Baldassarre, Matthias W. Lorenz, Tatjana Rundek, Mario Fritsch Neves, Jing Liu, Dirk Sander, Caroline Schmidt, Matthew Walters, Enrique Bernal, Gulay Asci, Rafael Gabriel, Michiel L. Bots, Bernhard Iglseder, Eric de Groot, Hirokazu Honda, Mark A. Espeland, Grace Parraga, Joline W.J. Beulens, Paolo Gresele, Pythia T. Nieuwkerk, Dianna Magliano, Michael J. Sweeting, Lars Lind, Kostas Kapellas, Tomi-Pekka Tuomainen, Maryam Kavousi, Frank P. Brouwers, Jean Philippe Empana, Markolf Hanefeld, Shuhei Okazaki, Menno V. Huisman, Jang Ho Bae, Daniel Staub, Aikaterini Papagianni, Gerhard Klingenschmid, Lisa Seekircher, Peter Willeit, Prabath W.B. Nanayakkara, Jackie F. Price, Johann Willeit, Radojica Stolić, Akihiko Kato, Alberico L. Catapano, Naveed Sattar, Christopher D. Byrne, Göran Bergström, Laura Calabresi, Robert Ekart, Michael H. Olsen, Michiaki Nagai, Michiel A. Van Agtmael, Marat Ezhov, Stefan Agewall, Eiichi Sato, Miles D. Witham, Eva Lonn, Ege Üniversitesi, Epidemiology, Internal medicine, Epidemiology and Data Science, ACS - Diabetes & metabolism, APH - Health Behaviors & Chronic Diseases, ACS - Heart failure & arrhythmias, Tschiderer, Lena, Seekircher, Lisa, Klingenschmid, Gerhard, Izzo, Raffaele, Baldassarre, Damiano, Iglseder, Bernhard, Calabresi, Laura, Liu, Jing, Price, Jackie F, Bae, Jang-Ho, Brouwers, Frank P, de Groot, Eric, Schmidt, Caroline, Bergström, Göran, Aşçi, Gülay, Gresele, Paolo, Okazaki, Shuhei, Kapellas, Kosta, Landecho, Manuel F, Sattar, Naveed, Agewall, Stefan, Zou, Zhi-Yong, Byrne, Christopher D, Nanayakkara, Prabath W B, Papagianni, Aikaterini, Witham, Miles D, Bernal, Enrique, Ekart, Robert, van Agtmael, Michiel A, Neves, Mario F, Sato, Eiichi, Ezhov, Marat, Walters, Matthew, Olsen, Michael H, Stolić, Radojica, Zozulińska-Ziółkiewicz, Dorota A, Hanefeld, Markolf, Staub, Daniel, Nagai, Michiaki, Nieuwkerk, Pythia T, Huisman, Menno V, Kato, Akihiko, Honda, Hirokazu, Parraga, Grace, Magliano, Dianna, Gabriel, Rafael, Rundek, Tatjana, Espeland, Mark A, Kiechl, Stefan, Willeit, Johann, Lind, Lar, Empana, Jean Philippe, Lonn, Eva, Tuomainen, Tomi-Pekka, Catapano, Alberico, Chien, Kuo-Liong, Sander, Dirk, Kavousi, Maryam, Beulens, Joline W J, Bots, Michiel L, Sweeting, Michael J, Lorenz, Matthias W, Willeit, Peter, Austrian Science Fund, Gastroenterology and Hepatology, Medical Psychology, APH - Mental Health, APH - Personalized Medicine, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Male, Aging, Clinical tests, medicine.medical_specialty, Population, Disease, Pulse Wave Analysis, Carotid Intima-Media Thickness, Risk Assessment, Predictive Value of Tests, Risk Factors, Internal medicine, Humans, Repeat measurements, Medicine, education, Prospective cohort study, Pulse wave velocity, Stroke, Aged, education.field_of_study, business.industry, Incidence (epidemiology), Middle Aged, Atherosclerosis, Cardiovascular disease, medicine.disease, Clinical trial, Cardiovascular Diseases, Research Design, Atherosclerosi, Female, Prospective studie, Geriatrics and Gerontology, business, Prospective studies, Consortium, Individual-participant data
Abstract

Atherosclerosis - the pathophysiological mechanism shared by most cardiovascular diseases - can be directly or indirectly assessed by a variety of clinical tests including measurement of carotid intima-media thickness, carotid plaque, ankle-brachial index, pulse wave velocity, and coronary artery calcium. the Prospective Studies of Atherosclerosis (Proof-ATHERO) consortium (https://clinicalepi.i-med.ac.at/research/proof-athero/) collates de-identified individual-participant data of studies with information on atherosclerosis measures, risk factors for cardiovascular disease, and incidence of cardiovascular diseases. It currently comprises 74 studies that involve 106,846 participants from 25 countries and over 40 cities. in summary, 21 studies recruited participants from the general population (n = 67,784), 16 from high-risk populations (n = 22,677), and 37 as part of clinical trials (n = 16,385). Baseline years of contributing studies range from April 1980 to July 2014; the latest follow-up was until June 2019. Mean age at baseline was 59 years (standard deviation: 10) and 50% were female. Over a total of 830,619 person-years of follow-up, 17,270 incident cardiovascular events (including coronary heart disease and stroke) and 13,270 deaths were recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum, respectively. the consortium is coordinated by the Clinical Epidemiology Team at the Medical University of Innsbruck, Austria. Contributing studies undergo a detailed data cleaning and harmonisation procedure before being incorporated in the Proof-ATHERO central database. Statistical analyses are being conducted according to pre-defined analysis plans and use established methods for individual-participant data meta-analysis. Capitalising on its large sample size, the multi-institutional collaborative Proof-ATHERO consortium aims to better characterise, understand, and predict the development of atherosclerosis and its clinical consequences. (c) 2020 S. Karger AG, Basel, Austrian Science Fund (FWF)Austrian Science Fund (FWF) [P 32488]; Dr.-Johannes-and-Hertha-Tuba Foundation, This work was funded by the Austrian Science Fund (FWF) (P 32488) and the Dr.-Johannes-and-Hertha-Tuba Foundation. Funders of individual studies contributing to the present analysis arelisted onthe Proof-ATHERO webpage(https://clinicalepi.i-med.ac.at/research/proof-athero/studies/).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results